baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /

2024-08-01 11:22:36 AM	Chg. +0.1300	Volume	Bid5:52:27 PM	Ask5:38:26 PM	Market Capitalization	Dividend Y.	P/E Ratio
2.7300EUR	+5.00%	100 Turnover: 273	2.5800Bid Size: 500	2.7300Ask Size: 500	91.25 mill.EUR	0.00%	-

GlobeNewswire 2021-05-26 Immatics Announces Changes to its Board of Directors

GlobeNewswire 2020-03-11 RedHill Biopharma Provides Update on Opaganib (Yeliva®)

GlobeNewswire 2018-10-19 ADC Contract Manufacturing Market, 2030

GlobeNewswire 2018-07-17 APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

GlobeNewswire 2017-11-16 Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%

GlobeNewswire 2017-08-24 Global Cell Line Development Services Market, 2027

GlobeNewswire 2017-07-06 Biopharmaceutical Contract Manufacturing Market, 2027

GlobeNewswire 2007-11-12 HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE

GlobeNewswire 2007-05-21 Clinical effectiveness and tolerability of Fosalvudine (HIV) confirmed

GlobeNewswire 2007-05-17 Fosfluridine Tidoxil shows effectiveness in Actinic Keratosis

GlobeNewswire 2007-02-05 Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis

GlobeNewswire 2007-01-10 Heidelberg Pharma becomes a Corporation

GlobeNewswire 2006-10-09 Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients

GlobeNewswire 2006-10-02 Heidelberg Pharma raises 16 million EUR (20 million USD) in series B-Round

HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /

If you wish to receive reply to your feedback, please provide your email address.